Search for other papers by Tristan Avril in
Google Scholar
PubMed
Search for other papers by Quentin Hennocq in
Google Scholar
PubMed
Search for other papers by Anne-Sophie Lambert in
Google Scholar
PubMed
Université Paris Cité, Faculté de Santé, UFR de Médecine, Paris, France
Search for other papers by Juliane Leger in
Google Scholar
PubMed
Search for other papers by Dominique Simon in
Google Scholar
PubMed
Université Paris Cité, Faculté de Santé, UFR de Médecine, Paris, France
Inserm UMR1185, Le Kremlin Bicetre, Paris, France
Search for other papers by Laetitia Martinerie in
Google Scholar
PubMed
Inserm UMR1185, Le Kremlin Bicetre, Paris, France
Paris-Saclay University, Paris, France
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
Objective
Newborns with congenital hypogonadotropic hypogonadism (CHH) have an impaired postnatal activation of the gonadotropic axis. Substitutive therapy with recombinant gonadotropins can be proposed to mimic physiological male mini-puberty during the first months of life. The aim of this study was to compare the clinical and biological efficacy of two treatment modalities of gonadotropins administration during mini-puberty in CHH neonates.
Design
Multicenter retrospective analytical epidemiological study comparing two treatments, pump vs injection, between 2004 and 2019.
Methods
Clinical (penile size, testis size, testicular descent) and biological parameters (serum concentrations of testosterone, anti-Müllerian hormone (AMH) and Inhibin B) were compared between the two groups by multivariate analyses.
Results
Thirty-five patients were included. A significantly higher increase in penile length and testosterone level was observed in the injection group compared to the pump group (+0.16 ± 0.02 mm vs +0.10 ± 0.02 mm per day, P = 0.002; and +0.04 ± 0.007 ng/mL vs +0.01 ± 0.008 ng/mL per day, P = 0.001). In both groups, significant increases in penile length and width, testosterone, AMH, and Inhibin B levels were observed, as well as improved testicular descent (odds ratio of not being in a scrotal position at the end of treatment = 0.97 (0.96; 0.99)).
Conclusions
Early postnatal administration of recombinant gonadotropins in CHH boys is effective in stimulating penile growth, Sertoli cell proliferation, and testicular descent, with both treatment modalities.
Search for other papers by Hong Tang in
Google Scholar
PubMed
Search for other papers by Xiaomei Jiang in
Google Scholar
PubMed
Search for other papers by Yu Hua in
Google Scholar
PubMed
Search for other papers by Heyue Li in
Google Scholar
PubMed
Search for other papers by Chunlan Zhu in
Google Scholar
PubMed
Search for other papers by Xiaobai Hao in
Google Scholar
PubMed
Search for other papers by Minhui Yi in
Google Scholar
PubMed
Search for other papers by Linxia Li in
Google Scholar
PubMed
Background
Polycystic ovary syndrome (PCOS) is an androgen disorder and ovarian dysfunction disease in women of reproductive age. The cell death of granulosa cells (GCs) plays an important role in the development of PCOS. However, the mechanism of GC death is still unclear.
Methods
In the current study, NEDD4L was found to be elevated in PCOS GEO (Gene Expression Omnibus) databases and mouse models. The cell viability was analyzed by CCK-8 and FDA staining. The expression of ferroptosis markers was assessed by ELISA and immunofluorescence. The direct interaction of GPX4 and NEDD4L was verified by co-immunoprecipitation assay.
Result
Functionally, results from CCK-8 and FDA staining demonstrated that NEDD4L inhibited the cell viability of KGN cells and NEDD4L increased the levels of iron, malonyldialdehyde, and reactive oxygen species and decreased glutathione levels. Moreover, the cell death of KGN induced by NEDD4L was blocked by ferroptosis inhibitor, suggesting that NEDD4L regulates KGN cell ferroptosis. Mechanistically, NEDD4L directly interacts with GPX4 and promotes GPX4 ubiquitination and degradation.
Conclusion
Taken together, our study indicated that NEDD4L facilitates GC ferroptosis by promoting GPX4 ubiquitination and degradation and contributes to the development of PCOS.
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Mette Bøgehave in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
OPEN, Open Patient data Explorative Network, Odense University Hospital, Region of Southern Denmark, Odense, Denmark
Search for other papers by Dorte Glintborg in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Jørgen Brodersen Gram in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Else-Marie Bladbjerg in
Google Scholar
PubMed
Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Marianne Skovsager Andersen in
Google Scholar
PubMed
Unit for Thrombosis Research, Department of Regional Health Research, University of Southern Denmark, Denmark
Search for other papers by Johannes Jakobsen Sidelmann in
Google Scholar
PubMed
Introduction
Hypogonadism is prevalent during opioid treatment, and low testosterone concentrations are associated with cardiovascular disease. The effect of testosterone replacement therapy (TRT) on the coagulation system in men with hypogonadism is not clarified. We investigate the effects of TRT on the tissue factor (TF) and contact activation pathways of coagulation in opioid-treated men.
Materials and methods
This was a double-blinded, placebo-controlled study in 37 men with total testosterone < 12 nmol/L randomized to 24 weeks of testosterone injections (n = 17) or placebo (n = 20). Variables of the coagulation system were analysed at baseline and after 24 weeks. Measurements included the TF pathway (endogenous thrombin potential (ETP) and peak thrombin), the contact activation pathway (endogenous kallikrein potential (EKP) and peak kallikrein), coagulation factors (FVII, FX, prothrombin, and FXII), and inhibitors (tissue factor pathway inhibitor (TFPI), protein C, protein S, antithrombin, and C1 esterase inhibitor (C1inh)). Between-group differences at 24 weeks were determined with analysis of covariance. Within-group changes in TRT and placebo were analysed with paired t-test.
Results
Between-group differences at 24 weeks were observed for ETP (P = 0.036), FVII (P = 0.044), FX (P = 0.015), prothrombin (P = 0.003), protein C (P = 0.004), and protein S (P = 0.038). Within the TRT group, ETP, peak thrombin, FVII, FX, prothrombin, TFPI, protein C, FXII, and C1inh decreased and protein S increased (all P < 0.05). Within the placebo group, coagulation outcomes were unchanged.
Conclusion
TRT affects the coagulation system in an anticoagulant direction through suppressed TF pathway in men with opioid-induced hypogonadism.
Search for other papers by Estelle Bonnet in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de psychopathologie du développement, Bron, France
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Centre de biologie et pathologie Est, Service d’hormonologie, d’endocrinologie moléculaire et des maladies rares, Bron, France
Search for other papers by Mathias Winter in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Centre de biologie et pathologie Est, Service d’hormonologie, d’endocrinologie moléculaire et des maladies rares, Bron, France
Search for other papers by Delphine Mallet in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service Endocrinologie Moléculaire et Maladies Rares, Bron, France
Search for other papers by Ingrid Plotton in
Google Scholar
PubMed
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
Search for other papers by Maryse Cartigny in
Google Scholar
PubMed
Search for other papers by Laetiti Martinerie in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
Search for other papers by Anne Bachelot in
Google Scholar
PubMed
Search for other papers by Frédéric Huet in
Google Scholar
PubMed
Search for other papers by Sabine Baron in
Google Scholar
PubMed
Search for other papers by Muriel Houang in
Google Scholar
PubMed
Search for other papers by Sylvie Soskin in
Google Scholar
PubMed
Search for other papers by Anne Lienhardt in
Google Scholar
PubMed
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
Search for other papers by Cyril Amouroux in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de chirurgie Uro-viscérale et de Transplantation de l’Enfant, Bron, France
Search for other papers by Aurore Bouty in
Google Scholar
PubMed
Search for other papers by Lise Duranteau in
Google Scholar
PubMed
Search for other papers by Rémi Besson in
Google Scholar
PubMed
Search for other papers by Alaa El Ghoneimi in
Google Scholar
PubMed
Search for other papers by Dinane Samara-Boustani in
Google Scholar
PubMed
Search for other papers by François Becmeur in
Google Scholar
PubMed
Search for other papers by Nicolas Kalfa in
Google Scholar
PubMed
Search for other papers by Françoise Paris in
Google Scholar
PubMed
Search for other papers by François Medjkane in
Google Scholar
PubMed
Hospices Civils de Lyon, Groupement Hospitalier Est, Service d’endocrinologie, Bron, France
Search for other papers by Aude Brac de la Perrière in
Google Scholar
PubMed
Centre National de Référence Maladies Rares du développement génital du fœtus à l’adulte DEV-GEN, Hospices Civils de Lyon, Bron, France
Search for other papers by Patricia Bretones in
Google Scholar
PubMed
Université Claude Bernard, Lyon, France
Search for other papers by Hervé Lejeune in
Google Scholar
PubMed
Centre National de Référence Maladies Rares du développement génital du fœtus à l’adulte DEV-GEN, Hospices Civils de Lyon, Bron, France
Université Claude Bernard, Lyon, France
Search for other papers by Marc Nicolino in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de chirurgie Uro-viscérale et de Transplantation de l’Enfant, Bron, France
Université Claude Bernard, Lyon, France
Search for other papers by Pierre Mouriquand in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Service de chirurgie Uro-viscérale et de Transplantation de l’Enfant, Bron, France
Search for other papers by Daniela-Brindusa Gorduza in
Google Scholar
PubMed
Centre National de Référence Maladies Rares du développement génital du fœtus à l’adulte DEV-GEN, Hospices Civils de Lyon, Bron, France
Search for other papers by Claire-Lise Gay in
Google Scholar
PubMed
Objectives
To examine the changes in diagnostic practices and clinical management of patients with 5α-reductase type 2 (SRD5A2) or 17β-hydroxysteroid dehydrogenase type 3 (HSD17B3) deficiency since molecular diagnoses became available.
Methods
Clinical, laboratory, and therapeutic data were retrieved from the medical records of 52 patients with a molecular diagnosis of SRD5A2 (n = 31) or HSD17B3 (n = 21) deficiency. Temporal trends regarding age at assessment and initial sex assignment over 1994–2020 were qualitatively analyzed. Age at molecular diagnosis was compared between two subgroups of patients according to their year of birth.
Results
Fifty-eight percent (n = 30) patients were diagnosed during the perinatal period, 33% (n = 17) during infancy, and 9% (n = 5) during adolescence or adulthood. Over the studied period, the patients’ age at initial assessment and diagnosis frankly decreased. The median (range) age at diagnostic confirmation was 10.5 (0–53.2) years for patients born before 2007 and 0.4 (0–9.3) years for those born in 2007 or later (P = 0.029). Genetic testing identified 27 different variants for the SRD5A2 gene (30% novel, n = 8) and 18 for the HSD17B3 gene (44% novel, n = 8). Before 2002, most patients were initially assigned as females (95%, n = 19), but this proportion dropped for those born later (44%, n = 14; P < 0.001). The influence of initial genital appearance on these decisions seemingly decreased in the most recent years. Therapeutic interventions differed according to the sex of rearing. Ten percent (n = 2) patients requested female-to-male reassignment during adulthood.
Conclusion
This study showed, over the past two decades, a clear trend toward earlier diagnosis and assignment of affected newborns as males.
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Search for other papers by Claus H Gravholt in
Google Scholar
PubMed
Search for other papers by Alberto Ferlin in
Google Scholar
PubMed
Search for other papers by Joerg Gromoll in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by Armin Raznahan in
Google Scholar
PubMed
Search for other papers by Sophie van Rijn in
Google Scholar
PubMed
Search for other papers by Alan D Rogol in
Google Scholar
PubMed
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Anne Skakkebæk in
Google Scholar
PubMed
Search for other papers by Nicole Tartaglia in
Google Scholar
PubMed
Search for other papers by Hanna Swaab in
Google Scholar
PubMed
The 3rd International Workshop on Klinefelter Syndrome, Trisomy X, and 47,XYY syndrome was held in Leiden, the Netherlands, on September 12–14, 2022.
Here, we review new data presented at the workshop and discuss scientific and clinical trajectories. We focus on shortcomings in knowledge and therefore point out future areas for research.
We focus on the genetics and genomics of supernumerary sex chromosome syndromes with new data being presented. Most knowledge centre specifically on Klinefelter syndrome, where aspects on testosterone deficiency and the relation to bone, muscle and fat were discussed, as was infertility and the treatment thereof. Both trisomy X and 47,XYY syndrome are frequently affected by infertility.
Transitioning of males with Klinefelter syndrome was addressed, as this seemingly simple process in practise is often difficult.
It is now realized that neurocognitive changes are pervasive in all supernumerary sex chromosome syndromes, which were extensively discussed. New intervention projects were also described, and exciting new data concerning these were presented.
Advocacy organizations were present, describing the enormous burden carried by parents when having to explain their child’s specific syndrome to most professionals whenever in contact with health care and education systems. It was also pointed out that most countries do not have health care systems that diagnose patients with supernumerary sex chromosome syndromes, thus pinpointing a clear deficiency in the current genetic testing and care models.
At the end of the workshop, a roadmap towards the development of new international clinical care guidelines for Klinefelter syndrome was decided.
Search for other papers by R H M Dykgraaf in
Google Scholar
PubMed
Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for other papers by S Schalekamp-Timmermans in
Google Scholar
PubMed
Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for other papers by M C Adank in
Google Scholar
PubMed
Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for other papers by S A A van den Berg in
Google Scholar
PubMed
Department of Internal Medicine, Academic Center for Thyroid Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for other papers by B M N van de Lang-Born in
Google Scholar
PubMed
Search for other papers by T I M Korevaar in
Google Scholar
PubMed
Search for other papers by A Kumar in
Google Scholar
PubMed
Search for other papers by B Kalra in
Google Scholar
PubMed
Search for other papers by G V Savjani in
Google Scholar
PubMed
Division of Obstetrics and Fetal Medicine, Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for other papers by E A P Steegers in
Google Scholar
PubMed
Search for other papers by Y V Louwers in
Google Scholar
PubMed
Search for other papers by J S E Laven in
Google Scholar
PubMed
Objective
The primary objective of this study is to establish maternal reference values of anti‐Müllerian hormone (AMH) in a fertile multi-ethnic urban pregnant population and to evaluate the effect of gestational age. The secondary objective of this study is to explore the association between AMH and placental biomarkers.
Design
This study was embedded in the Generation R Study, an ongoing population-based prospective cohort study from early pregnancy onwards.
Setting
City of Rotterdam, the Netherlands, out of hospital setting.
Patients
In 5806 women, serum AMH levels were determined in early pregnancy (median 13.5 weeks; 95% range 10.5–17.2).
Intervention(s)
None.
Main outcome measures
Maternal AMH levels in early pregnancy and its association with placental biomarkers, including human chorionic gonadotrophin (hCG), soluble fms-like tyrosine kinase-1 (sFLT), and placental growth factor (PLGF).
Results
A nomogram of AMH in early pregnancy was developed. Serum AMH levels showed a decline with advancing gestational age. Higher AMH levels were associated with a higher level of the placental biomarkers hCG and sFLT in early pregnancy. This last association was predominantly mediated by hCG. AMH levels were negatively associated with PLGF levels.
Conclusion
In this large study, we show that AMH levels in early pregnancy decrease with advancing gestational age. The association between AMH and the placental biomarkers hCG, sFLT, and PLGF suggests a better placental development with lower vascular resistance in mothers with higher AMH levels. Hence, AMH might be useful in predicting adverse pregnancy outcomes due to impaired placental development.
Molecular Reproductive Research Group, Department of Translational Medicine, Lund University, Malmö, Sweden
Institute of Molecular Biology and Biotechnology, FORTH, Heraklion, Greece
Search for other papers by Christos Tsatsanis in
Google Scholar
PubMed
Reproductive Medicine Centre, Skåne University Hospital Malmö, Malmö, Sweden
Search for other papers by Angel Elenkov in
Google Scholar
PubMed
Search for other papers by Irene Leijonhufvud in
Google Scholar
PubMed
Search for other papers by Katerina Vaporidi in
Google Scholar
PubMed
Search for other papers by Åsa Tivesten in
Google Scholar
PubMed
Reproductive Medicine Centre, Skåne University Hospital Malmö, Malmö, Sweden
Search for other papers by Aleksander Giwercman in
Google Scholar
PubMed
Background
The risk of inflammatory diseases is sex-dependent, but it remains unknown whether this is due to the impact of sex hormones or sex chromosomes. Transgender individuals represent a unique cohort for studying the relative influence of endocrine and chromosomal factors. Here we compared serum levels of B-cell activating-factor (BAFF) and tumor necrosis factor (TNF) in transgender men (TM), transgender women (TW), cisgender women (CW) and cisgender men (CM).
Methods
BAFF and TNF were measured in the serum of 26 CW, 30 CM, 27 TM and 16 TW individuals. To determine the responsiveness of immune cells, TNF was measured in bacterial lipopolysaccharide (LPS)-treated peripheral leukocytes.
Results
BAFF was higher in CF (998 pg/mL) and TW (973 pg/mL) compared to CM (551 pg/mL) (P < 0.0001) and TM (726 pg/mL) (P < 0.0001). No difference in BAFF levels was shown between subjects grouped according to the number of X chromosomes. TNF was higher in CM (174 pg/mL) than TW (2.3 pg/mL) (P = 0.027) and TM (27.4 pg/mL) (P = 0.028). LPS-induced TNF was higher in CM (2524 pg/mL) and TM (2078 pg/mL) than in CW (1332 pg/mL) (both P < 0.0001) and TW (1602 pg/mL) (both P = 0.009).
Discussion
Sex hormones and sex chromosomes have different impacts on cytokines involved in the sex-dependent inflammatory response. The concentration of BAFF and LPS-stimulated TNF secretion depended on sex hormone levels, whereas basal TNF was regulated by both sex hormone-dependent and -independent factors.
Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization, Disaster Reconstruction Center, Iwate Medical University, Yahaba, Japan
Search for other papers by Shiori Minabe in
Google Scholar
PubMed
Search for other papers by Kinuyo Iwata in
Google Scholar
PubMed
Search for other papers by Youki Watanabe in
Google Scholar
PubMed
Search for other papers by Hirotaka Ishii in
Google Scholar
PubMed
Faculty of Health Science, Bukkyo University, Kyoto, Japan
Search for other papers by Hitoshi Ozawa in
Google Scholar
PubMed
The nutritional environment during development periods induces metabolic programming, leading to metabolic disorders and detrimental influences on human reproductive health. This study aimed to determine the long-term adverse effect of intrauterine malnutrition on the reproductive center kisspeptin-neurokinin B-dynorphin A (KNDy) neurons in the hypothalamic arcuate nucleus (ARC) of female offspring. Twelve pregnant rats were divided into ad-lib-fed (control, n = 6) and 50% undernutrition (UN, n = 6) groups. The UN group was restricted to 50% daily food intake of the control dams from gestation day 9 until term delivery. Differences between the two groups in terms of various maternal parameters, including body weight (BW), pregnancy duration, and litter size, as well as birth weight, puberty onset, estrous cyclicity, pulsatile luteinizing hormone (LH) secretion, and hypothalamic gene expression of offspring, were determined. Female offspring of UN dams exhibited low BW from birth to 3 weeks, whereas UN offspring showed signs of precocious puberty; hypothalamic Tac3 (a neurokinin B gene) expression was increased in prepubertal UN offspring, and the BW at the virginal opening was lower in UN offspring than that in the control group. Interestingly, the UN offspring showed significant decreases in the number of KNDy gene-expressing cells after 29 weeks of age, but the number of ARC kisspeptin-immunoreactive cells, pulsatile LH secretions, and estrous cyclicity were comparable between the groups. In conclusion, intrauterine undernutrition induced various changes in KNDy gene expression depending on the life stage. Thus, intrauterine undernutrition affected hypothalamic developmental programming in female rats.
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Nathalie Ly in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Search for other papers by Sophie Dubreuil in
Google Scholar
PubMed
EndoERN, APHP Consortium Pitie Salpetriere Hospital, Necker Hospital, Paris, France
Sorbonne University, Paris, France
Search for other papers by Philippe Touraine in
Google Scholar
PubMed
Objective
Growth hormone (GH) and insulin-like growth factors (IGFs) are not mandatory for reproductive life, but data suggest their synergistic action with follicle-stimulating hormone throughout ovarian folliculogenesis. We aimed to evaluate the association of IGF-1 level on clinical pregnancy rate after ovarian stimulation, with or without intrauterine insemination, in women with GH deficiency (GHD) treated with GH replacement therapy (GHRT) at conception.
Design and methods
Data from 19 women with both GHD and hypogonadotropic hypogonadism referred to our reproductive medicine department were retrospectively collected. IGF-1 levels were assessed in a single laboratory, and values were expressed in s.d. from the mean.
Results
Amongst the seven patients receiving GHRT during ovarian stimulation, higher IGF-1 levels were significantly associated with clinical pregnancy (+0.4 s.d. vs–1.6 s.d., P = 0.03). Amongst the 24 pregnancies obtained by the 19 infertile patients, pregnancy loss was less frequent with the addition of GHRT than without (1 miscarriage out of 8 total pregnancies vs 4 miscarriages out of 16 total pregnancies).
Conclusions
This is the first study evaluating the association of IGF-1 level on clinical pregnancy rate in GH-treated women at conception. When taking care of female infertility due to hypogonadotropic hypogonadism, practitioners should enquire about the associated GHD and IGF-1 levels. To ensure higher clinical pregnancy chances, practitioners should aim for IGF-1 values at conception, ranging from 0 s.d. to +2 s.d., and, if necessary, could discuss initiation or increase GH treatment. Prospective studies should help strengthen our results.
Search for other papers by Małgorzata Więcek in
Google Scholar
PubMed
Search for other papers by Jakub Gawlik in
Google Scholar
PubMed
Search for other papers by Zuzanna Nowak in
Google Scholar
PubMed
Search for other papers by Aneta Gawlik in
Google Scholar
PubMed
Loss of fertility is one of the most important concerns facing Turner syndrome (TS) patients as they transition into adult health care. Due to the limited and rapidly decreasing ovarian reserve, many TS patients require fertility preservation (FP) techniques to preserve their reproductive potential until they are ready to pursue procreation. One has to also remember about the additional risks connected with pregnancy in TS patients. In order to determine the optimal time for introducing FP techniques and decrease the chance of an unnecessary intervention, markers and procedures assessing ovarian reserve have been developed. The exposure to potential cardiovascular complications should be determined before FP to avoid unnecessary procedures in patients with potential contraindications to pregnancy. The aim of the present review is to answer the following three questions important for successful preservation of fertility and safe pregnancy in TS: which markers of ovarian reserve should be used as selection criteria for FP? Which methods of FP are the safest and most effective? Are there any cardiovascular contraindications to FP? For each of those questions, separate literature searches have been conducted. A total of 86 articles have been included in this review: 34 for the first question, 35 for the second, and 17 for the third. Ovarian reserve markers and cardiovascular contraindications to pregnancy should be established before FP; hoverer, there are no unambiguous indicators as to which patients should be disqualified from the FP and more evidence is needed in this subject.
